A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
Clinical trial NCT04437511 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04437511
- Sponsor
- Eli Lilly and Company
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-06-19
- Primary completion
- 2023-04-14
- Enrollment
- 1736
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.